. 2018 Mar 30;9(24):17014–17027. doi: 10.18632/oncotarget.24795

Table 1. Clinical characteristics of the TRIMEL-loaded DCs treated melanoma patients.

Patient code	Gender	AJCC stage	Primary tumor localization	Metastasis	Additional treatment	DTH response	Overall survival (months)
MT061^p	M	IV	Urethral meatus	M1c	CTX	–	10.8^†
MT065^p	F	IV	Scalp	M1c	CTX	–	5.7^†
MT066^p	M	IIIC	Abdominal wall	ND	DTIC, RT	+	47.7^†
MT072^p	M	IV	Dorsal	M1c	NA	–	15.2^†
MT076^p	F	IV	Left foot	M1b	RT	+	35.1^†
MT079^p,g	F	IV	Left flank	M1c	Surgery	–	9^†
MT080^p,g	M	IV	Palate	M1c	Surgery, RT	+	68.3
MT083^g	M	IIIC	Right hand	N4	Surgery	–	17^†
MT084^g	M	IIIC	Right foot	N4	Surgery	+	65.3^†
MT087^g	M	IV	Right hand	M1b	Surgery, RT	NT	1.4^†
MT089^g	M	IV	Right foot	M1b	Surgery, RT	NT	6.2^†
MT091^p,g	M	IV	Scalp	M1c	Surgery, RT	+	50.6^†
MT093^g	F	IV	Uveal melanoma	M1c	Surgery	+	64.9
MT094^g	M	IV	Head/Neck	M1c	Surgery	NT	3.4^†
MT096^g	M	IIIA	Dorsal	N2a	Surgery	+	31^†
MT098^g	M	IV	Right hand	M1c	Surgery	NT	2.6^†
MT101^g	M	IV	Dorsal/Right leg	M1a	Surgery	–	63.9
MT105^p	F	IIIA	Right leg	N2a	NA	–	63.5
MT109^p	F	IV	ND	M1c	Surgery	NT	2.4^†
MT114^p	M	IV	Thoracic wall	M1c	RT, IFN-α	–	10.7^†
MT122^p	M	IIIC	Left leg	ND	NA	+	29.9^†
MT123^p	M	IV	Left flank	M1c	RT	–	6.9^†
MT127^p	F	IV	Left foot	M1b	NA	+	12.1^†
MT128^p	F	IIIB	Right shoulder	N2c	RT	+	56.5
MT132^p	M	IV	Uveal melanoma	M1c	DTIC	–	43.6^†
MT141^p	M	IV	Knee	M1c	RT	–	20.5^†
MT147^p	F	IV	Left leg	M1b	RT	+	12.8^†
MT158^p	M	IV	Right shoulder	M1a	Surgery, RT	+	10.2^†

Abbreviations: p, protein expression analysis; g, gen expression analysis; F, Female; M, Male; AJCC, American Joint Committee on Cancer; ND, Not determined; RT, Radiotherapy; CTX, Chemotherapy; DTIC, Dacarbazine; NA, Not apply; NT, Not tested; ^†, Deceased.